Dr. Gandía has a particular interest in the development of new methodologies within the research groups he has worked with, always in the areas of neuroscience and pharmacology.

During his predoctoral studies, he moved to Toronto (Department of Biochemistry, University of Toronto) to learn and apply the membrane yeast two-hybrid technique for the characterization of interacting proteins for 50 medically relevant G protein-coupled receptors (GPCRs). The results obtained during the project’s development were published in a high-impact article in collaboration with several laboratories (Sokolina et al., 2017).

During his postdoctoral stay at INRA (2015–2019), he built a nanobody library against a subset of GPCRs, the exploitation of which has been shared by the team with research groups from other countries.

In his subsequent postdoctoral period at the Université de Tours (2019–2021), his interest in implementing a broader range of behavioral tests in murine models of ALS allowed the research group to conduct more precise evaluations of effective therapies for amyotrophic lateral sclerosis.

He is currently a member of the Medicinal Chemistry and Synthesis group at IQAC-CSIC, where he implements new biological techniques for the pharmacological characterization of recently synthesized molecules, with a special emphasis on their application in photopharmacology.